Because elevated ubiquitin ligase atrogin-1/MAFbx and MuRF1 mediate skeletal muscle wasting associated with various catabolic conditions, the signaling pathways involved in the upregulation of these genes under pathological conditions are considered therapeutic targets. AKT and NF-κB have been previously shown to regulate the expression of atrogin-1/MAFbx or MuRF1, respectively. In addition, we recently found that p38 MAPK mediates TNF-α upregulation of atrogin-1/MAFbx expression, suggesting that multiple signaling pathways mediate muscle wasting in inflammatory diseases. To date, however, these advances have not resulted in a practical clinical intervention for disease-induced muscle wasting. In the present study, we tested the effect of curcumin-a non-toxic anti-inflammatory reagent that inhibits p38 and NF-κB-on lipopolysaccharide (LPS)-induced muscle wasting in mice. Daily intraperitoneal (i.p.) injection of curcumin (10-60 μg/kg) for 4 days inhibited, in a dose-dependent manner, the LPS-stimulated (1 mg/kg, i.p.) increase of atrogin-1/MAFbx expression in gastrocnemius and extensor digitorum longus (EDL) muscles, resulting in the attenuation of muscle protein loss. It should also be noted that curcumin administration did not alter the basal expression of atrogin-1/MAFbx, nor did it affect LPS-stimulated MuRF1 and polyubiquitin expression. LPS activated p38 and NF-κB, while inhibiting AKT; whereas, curcumin administration inhibited LPS-stimulated p38 activation, without altering the effect of LPS on NF-κB and AKT. These results indicate that curcumin is effective in blocking LPS-induced loss of muscle mass through the inhibition of p38-mediated upregulation of atrogin-1/MAFbx. Keywords endotoxemia; ubiquitin-proteasome pathway; p38; AKT; NF-κB Muscle wasting is a major feature of the cachexia associated with such diseases as sepsis, cancer, AIDS, diabetes, uremia, congestive heart failure, and chronic obstructive pulmonary disease (COPD) [Hasselgren, 1995;Tisdale, 1997]. Muscle wasting increases patient morbidity and mortality through disability, injury, osteoporosis, impairment of respiratory function, and depletion of the free amino acid pool for enzyme and antibody production. The progressive loss of body protein becomes lethal when it depletes approximately 40% of lean body mass [Winick, 1979]. However, to date, no drug has been approved for muscle wasting. Muscle wasting is primarily caused by accelerated muscle protein breakdown via the ubiquitin-proteasome pathway . Proteins degraded by this pathway are first covalently linked to a chain of ubiquitin molecules that marks them for rapid breakdown by the 26S proteasome. The selectivity of ubiquitin targeting is primarily a function of ubiquitin ligase (E3 protein) [Hershko and Ciechanover, 1998]. Two muscleenriched ubiquitin ligases, atrogin-1/MAFbx and MuRF1, are rate limiting for muscle protein loss in various catabolic conditions. Expression of these two ubiquitin ligases is upregulated in the muscle of various animal models of muscle atrophy,...